InvestorsObserver
×
News Home

Is Viking Therapeutics Inc (VKTX) a Bad Choice in Biotechnology Wednesday?

Wednesday, November 01, 2023 10:30 AM | InvestorsObserver Analysts

Mentioned in this article

Is Viking Therapeutics Inc (VKTX) a Bad Choice in Biotechnology Wednesday?

The 74 rating InvestorsObserver gives to Viking Therapeutics Inc (VKTX) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 93 percent of stocks in the Biotechnology industry, VKTX’s 74 overall rating means the stock scores better than 74 percent of all stocks.

Overall Score - 74
VKTX has an Overall Score of 74. Find out what this means to you and get the rest of the rankings on VKTX!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 74 would rank higher than 74 percent of all stocks.
This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Viking Therapeutics Inc Stock Today?

Viking Therapeutics Inc (VKTX) stock is down -2.64% while the S&P 500 is higher by 0.7% as of 10:16 AM on Wednesday, Nov 1. VKTX is lower by -$0.26 from the previous closing price of $9.81 on volume of 336,232 shares. Over the past year the S&P 500 is up 9.52% while VKTX is higher by 118.54%. VKTX lost -$0.92 per share the over the last 12 months. Click Here to get the full Stock Report for Viking Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App